Signed results revised; revenue up 23.7%, net profit turns positive and CFO appointed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter to 30 September 2026: revenue from operations was Rs 1,013.31 lakh versus Rs 819.00 lakh a year earlier, up 23.7%. After-tax profit was Rs 183.71 lakh versus a loss of Rs 16.93 lakh. Pre-tax loss was Rs 89.74 lakh after a Rs 35.43 lakh exceptional charge; tax benefits drove profit. Half-year operating cash flow was negative; borrowings exceeded equity. It replaces improperly signed results. CFO Tejas Basrani starts 12 November 2026.
Revenue grew and EBITDA margin expanded, but pre-tax loss, exceptional charge, negative cash flow and high borrowings keep financial risk elevated.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹12.03 Cr | ₹5.53 Cr | +117.3% |
| Operating profit | −₹0.92 Cr | −₹0.63 Cr | loss widened |
| Profit after tax | −₹0.90 Cr | −₹0.60 Cr | loss widened |
| EBITDA margin | -4.3% | -3.9% | −0.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.